{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:59:23Z","timestamp":1789235963734,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,28]]},"DOI":"10.7759\/cureus.41116","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T06:07:44Z","timestamp":1688018864000},"source":"Crossref","is-referenced-by-count":3,"title":["Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options"],"prefix":"10.7759","author":[{"given":"Noah J","family":"Spillers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norris C","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni H","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lavespere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Pavlickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Acetaminophen | Consumer Healthcare Products Association. (2023). Accessed. May 2, 2023: https:\/\/www.chpa.org\/our-issues\/otc-medicines\/acetaminophen."},{"key":"ref2","unstructured":"Acetaminophen Market. (2023). Accessed. May 2, 2023: https:\/\/www.futuremarketinsights.com\/reports\/acetaminophen-market."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz R","year":"2021","unstructured":"Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas). 2021, 57:895. 10.3390\/medicina57090895","journal-title":"Medicina (Kaunas)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States Adults","volume":"136","author":"Hsu DY","year":"2016","unstructured":"Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States Adults. J Invest Dermatol. 2016, 136:1387-97. 10.1016\/j.jid.2016.03.023","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.148","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis; extensive review of reports of drug-induced etiologies, and possible therapeutic modalities","volume":"6","author":"Fakoya AO","year":"2018","unstructured":"Fakoya AO, Omenyi P, Anthony P, Anthony F, Etti P, Otohinoyi DA, Olunu E. Stevens-Johnson syndrome and toxic epidermal necrolysis; extensive review of reports of drug-induced etiologies, and possible therapeutic modalities. Open Access Maced J Med Sci. 2018, 6:730-8. 10.3889\/oamjms.2018.148","journal-title":"Open Access Maced J Med Sci"},{"key":"ref6","article-title":"Acetaminophen induced Steven Johnson syndrome-toxic epidermal necrolysis overlap","volume":"62","author":"Khuwaja A","year":"2012","unstructured":"Khuwaja A, Shahab A, Hussain SA. Acetaminophen induced Steven Johnson syndrome-toxic epidermal necrolysis overlap. J Pak Med Assoc. 2012, 62:524-7.","journal-title":"J Pak Med Assoc"},{"key":"ref7","unstructured":"A review of published cases of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of acetaminophen. Cutaneous and Ocular Toxicology: Vol 40, No 3. (2023). Accessed: May 2, 2023: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/15569527.2021.1942896."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6294","article-title":"Acetaminophen-induced Stevens-Johnson syndrome with lethal lung injury: a case report","volume":"10","author":"Nakamura R","year":"2022","unstructured":"Nakamura R, Ochi F, Chisaka T, Jogamoto T, Eguchi M. Acetaminophen-induced Stevens-Johnson syndrome with lethal lung injury: a case report. Clin Case Rep. 2022, 10:e6294. 10.1002\/ccr3.6294","journal-title":"Clin Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7010012","article-title":"Hypersensitivity reactions in serious adverse events reported for paracetamol in the EudraVigilance database, 2007-2018","volume":"7","author":"Popio\u0142ek I","year":"2019","unstructured":"Popio\u0142ek I, Piotrowicz-W\u00f3jcik K, Porebski G. Hypersensitivity reactions in serious adverse events reported for paracetamol in the EudraVigilance database, 2007-2018. Pharmacy (Basel). 2019, 7:12. 10.3390\/pharmacy7010012","journal-title":"Pharmacy (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2014.4.1.68","article-title":"Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen","volume":"4","author":"Kim EJ","year":"2014","unstructured":"Kim EJ, Lim H, Park SY, et al.. Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen. Asia Pac Allergy. 2014, 4:68-72. 10.5415\/apallergy.2014.4.1.68","journal-title":"Asia Pac Allergy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13445","article-title":"Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database","volume":"84","author":"Lebrun-Vignes B","year":"2018","unstructured":"Lebrun-Vignes B, Guy C, Jean-Pastor MJ, Gras-Champel V, Zenut M. Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. Br J Clin Pharmacol. 2018, 84:331-8. 10.1111\/bcp.13445","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/srep04862","article-title":"Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement","volume":"4","author":"Ueta M","year":"2014","unstructured":"Ueta M, Kaniwa N, Sotozono C, et al.. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep. 2014, 4:4862. 10.1038\/srep04862","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23537","article-title":"Results of detailed investigations into Stevens-Johnson syndrome with severe ocular complications","volume":"59","author":"Ueta M","year":"2018","unstructured":"Ueta M. Results of detailed investigations into Stevens-Johnson syndrome with severe ocular complications. Invest Ophthalmol Vis Sci. 2018, 59:183-91. 10.1167\/iovs.17-23537","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649661","article-title":"Findings by an international collaboration on SJS\/TEN with severe ocular complications","volume":"8","author":"Ueta M","year":"2021","unstructured":"Ueta M. Findings by an international collaboration on SJS\/TEN with severe ocular complications. Front Med (Lausanne). 2021, 8:649661. 10.3389\/fmed.2021.649661","journal-title":"Front Med (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41439-019-0082-6","article-title":"Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals","volume":"6","author":"Ueta M","year":"2019","unstructured":"Ueta M, Nakamura R, Saito Y, et al.. Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. Hum Genome Var. 2019, 6:50. 10.1038\/s41439-019-0082-6","journal-title":"Hum Genome Var"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52619-2","article-title":"Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing","volume":"9","author":"Nakatani K","year":"2019","unstructured":"Nakatani K, Ueta M, Khor SS, et al.. Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. Sci Rep. 2019, 9:16240. 10.1038\/s41598-019-52619-2","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317315","article-title":"Association of HLA polymorphisms and acetaminophen-related Steven-Johnson syndrome with severe ocular complications in Thai population","volume":"106","author":"Jongkhajornpong P","year":"2022","unstructured":"Jongkhajornpong P, Ueta M, Lekhanont K, et al.. Association of HLA polymorphisms and acetaminophen-related Steven-Johnson syndrome with severe ocular complications in Thai population. Br J Ophthalmol. 2022, 106:884-8. 10.1136\/bjophthalmol-2020-317315","journal-title":"Br J Ophthalmol"},{"key":"ref18","unstructured":"Acetaminophen | FDA. (2023). Accessed. May 2, 2023: https:\/\/www.fda.gov\/drugs\/information-drug-class\/acetaminophen."},{"key":"ref19","unstructured":"Acetaminophen (Oral Route, Rectal Route) Proper Use - Mayo Clinic. (2023). Accessed. May 2, 2023: https:\/\/www.mayoclinic.org\/drugs-supplements\/acetaminophen-oral-route-rectal-route\/proper-use\/drg-20068480."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000150","article-title":"PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses","volume":"25","author":"Mazaleuskaya LL","year":"2015","unstructured":"Mazaleuskaya LL, Sangkuhl K, Thorn CF, FitzGerald GA, Altman RB, Klein TE. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015, 25:416-26. 10.1097\/FPC.0000000000000150","journal-title":"Pharmacogenet Genomics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-2999(00)00207-7","article-title":"The anandamide transport inhibitor AM404 activates vanilloid receptors","volume":"396","author":"Zygmunt PM","year":"2000","unstructured":"Zygmunt PM, Chuang H, Movahed P, et al.. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000, 396:39-42. 10.1016\/s0014-2999(00)00207-7","journal-title":"Eur J Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2006.00250.x","article-title":"Paracetamol: new vistas of an old drug","volume":"12","author":"Bertolini A","year":"2006","unstructured":"Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006, 12:250-75. 10.1111\/j.1527-3458.2006.00250.x","journal-title":"CNS Drug Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2174\/157015906778019527","article-title":"Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes","volume":"4","author":"Manzanares J","year":"2006","unstructured":"Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006, 4:239-57. 10.2174\/157015906778019527","journal-title":"Curr Neuropharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01822-z","article-title":"Risk of COVID-19 diagnosis and hospitalisation in patients with osteoarthritis or back pain treated with ibuprofen compared to other NSAIDs or paracetamol: a network cohort study","volume":"83","author":"Xie J","year":"2023","unstructured":"Xie J, Brash JT, Turkmen C, et al.. Risk of COVID-19 diagnosis and hospitalisation in patients with osteoarthritis or back pain treated with ibuprofen compared to other NSAIDs or paracetamol: a network cohort study. Drugs. 2023, 83:249-63. 10.1007\/s40265-022-01822-z","journal-title":"Drugs"},{"key":"ref25","unstructured":"A Review of the Management of Stevens-Johnson Syndrome. (2023). Accessed. May 2, 2023: https:\/\/journals.lww.com\/aenjournal\/Fulltext\/2019\/01000\/A_Review_of_the_Management_of_Stevens_Johnson.10.aspx."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau JC","year":"1997","unstructured":"Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997, 24:726-9. 10.1111\/j.1346-8138.1997.tb02524.x","journal-title":"J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.83.216","article-title":"A review of the pathogenesis of toxic epidermal necrolysis","volume":"83","author":"Kinoshita Y","year":"2016","unstructured":"Kinoshita Y, Saeki H. A review of the pathogenesis of toxic epidermal necrolysis. J Nippon Med Sch. 2016, 83:216-22. 10.1272\/jnms.83.216","journal-title":"J Nippon Med Sch"},{"key":"ref28","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"118","author":"Eginli A","year":"2017","unstructured":"Eginli A, Shah K, Watkins C, et al.. Stevens-Johnson syndrome and toxic epidermal necrolysis. ClinicalKey. 2017, 118:143-7.","journal-title":"ClinicalKey"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_889_19","article-title":"Nikolsky's sign: a pathognomic boon","volume":"9","author":"Maity S","year":"2020","unstructured":"Maity S, Banerjee I, Sinha R, Jha H, Ghosh P, Mustafi S. Nikolsky's sign: a pathognomic boon. J Family Med Prim Care. 2020, 9:526-30. 10.4103\/jfmpc.jfmpc_889_19","journal-title":"J Family Med Prim Care"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko E","year":"2005","unstructured":"Letko E, Papaliodis DN, Papaliodis GN, et al.. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005, 94:419-36. 10.1016\/S1081-1206(10)61112-X","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula P","year":"2013","unstructured":"Sekula P, Dunant A, Mockenhaupt M, et al.. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013, 133:1197-204. 10.1038\/jid.2012.510","journal-title":"J Invest Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung WH","year":"2016","unstructured":"Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016, 43:758-66. 10.1111\/1346-8138.13430","journal-title":"J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt M","year":"2011","unstructured":"Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011, 7:803-13; quiz 814-15. 10.1586\/eci.11.66","journal-title":"Expert Rev Clin Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07023.x","article-title":"The CD40\/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"154","author":"Caproni M","year":"2006","unstructured":"Caproni M, Torchia D, Schincaglia E, et al.. The CD40\/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum. Br J Dermatol. 2006, 154:319-24. 10.1111\/j.1365-2133.2005.07023.x","journal-title":"Br J Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul C","year":"1996","unstructured":"Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996, 134:710-14. 10.1111\/j.1365-2133.1996.tb06976.x","journal-title":"Br J Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle I","year":"2013","unstructured":"Viard-Leveugle I, Gaide O, Jankovic D, et al.. TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013, 133:489-98. 10.1038\/jid.2012.330","journal-title":"J Invest Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas SJ","year":"2002","unstructured":"Posadas SJ, Padial A, Torres MJ, et al.. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002, 109:155-61. 10.1067\/mai.2002.120563","journal-title":"J Allergy Clin Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.10-RAI-0261","article-title":"Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Chung WH","year":"2010","unstructured":"Chung WH, Hung SI. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010, 59:325-32. 10.2332\/allergolint.10-RAI-0261","journal-title":"Allergol Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa N","year":"2008","unstructured":"Kaniwa N, Saito Y, Aihara M, et al.. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008, 9:1617-22. 10.2217\/14622416.9.11.1617","journal-title":"Pharmacogenomics"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(75)90482-9","article-title":"Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution","volume":"66","author":"Bose KS","year":"1975","unstructured":"Bose KS, Sarma RH. Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution. Biochem Biophys Res Commun. 1975, 66:1173-9. 10.1016\/0006-291x(75)90482-9","journal-title":"Biochem Biophys Res Commun"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen A","year":"2022","unstructured":"Jacobsen A, Olabi B, Langley A, et al.. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome. Cochrane Database Syst Rev. 2022, 3:CD013130. 10.1002\/14651858.CD013130.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/167898-association-of-acetaminophen-with-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pharmacologic-considerations-and-treatment-options","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:43Z","timestamp":1707508843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/167898-association-of-acetaminophen-with-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pharmacologic-considerations-and-treatment-options"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.41116","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}